Lawrence Lee1, Justin Kelly2, George J Nassif2, Sam B Atallah2, Matthew R Albert2, Ravi Shridhar3, John R T Monson2. 1. Center for Colon and Rectal Surgery, Florida Hospital, 2401 North Orange Ave, Suite 240, Orlando, FL, 32804, USA. lawrence.lee.md@flhosp.org. 2. Center for Colon and Rectal Surgery, Florida Hospital, 2401 North Orange Ave, Suite 240, Orlando, FL, 32804, USA. 3. Department of Radiation Oncology, Florida Hospital, Orlando, FL, USA.
Abstract
BACKGROUND: Local excision (LE) alone is associated with worse survival compared to radical surgery (RS) for T2 rectal cancer, but LE with additional chemoradiation (CRT) may improve outcomes. The objective of this study was to compare combined CRT and LE versus RS for T2 rectal cancer. METHODS: The 2004-2014 National Cancer Database was queried for patients with T2N0M0 rectal cancer undergoing LE with neoadjuvant(NA-CRT + LE) or adjuvant(LE + Adj-CRT) CRT, or RS. The main outcome was 5-year overall survival (OS). Cox proportional hazards was used to determine the independent effect of treatment on OS. RESULTS: A total of 4822 patients were included (4367 RS, 242 CRT + LE, 213 LE + Adj-CRT). Mean follow-up was 48.6 (SD28.5) months. There were no differences in patient characteristics, but more high-risk features in the LE + Adj-CRT group. There were no differences in 90-day mortality. Five-year OS was similar (RS 77.4% vs. CRT + LE 76.1% vs. LE + Adj-CRT 79.7%, p = 0.786). Older age, male gender, and higher Charlson score were independently associated with worse OS, whereas treatment type was not. If 90-day mortality was excluded, LE + Adj-CRT was independently associated with worse OS compared to RS. CONCLUSIONS: CRT with LE for T2N0M0 rectal cancer was not associated with worse OS compared to RS, and may be a viable treatment modality.
BACKGROUND: Local excision (LE) alone is associated with worse survival compared to radical surgery (RS) for T2 rectal cancer, but LE with additional chemoradiation (CRT) may improve outcomes. The objective of this study was to compare combined CRT and LE versus RS for T2 rectal cancer. METHODS: The 2004-2014 National Cancer Database was queried for patients with T2N0M0 rectal cancer undergoing LE with neoadjuvant(NA-CRT + LE) or adjuvant(LE + Adj-CRT) CRT, or RS. The main outcome was 5-year overall survival (OS). Cox proportional hazards was used to determine the independent effect of treatment on OS. RESULTS: A total of 4822 patients were included (4367 RS, 242 CRT + LE, 213 LE + Adj-CRT). Mean follow-up was 48.6 (SD28.5) months. There were no differences in patient characteristics, but more high-risk features in the LE + Adj-CRT group. There were no differences in 90-day mortality. Five-year OS was similar (RS 77.4% vs. CRT + LE 76.1% vs. LE + Adj-CRT 79.7%, p = 0.786). Older age, male gender, and higher Charlson score were independently associated with worse OS, whereas treatment type was not. If 90-day mortality was excluded, LE + Adj-CRT was independently associated with worse OS compared to RS. CONCLUSIONS: CRT with LE for T2N0M0 rectal cancer was not associated with worse OS compared to RS, and may be a viable treatment modality.
Entities:
Keywords:
Chemoradiation; Local excision; Rectal cancer; Total Mesorectal Excision
Authors: Giancarlo D'Ambrosio; Alessandro M Paganini; Andrea Balla; Silvia Quaresima; Pietro Ursi; Paolo Bruzzone; Andrea Picchetto; Fabrizio I Mattei; Emanuele Lezoche Journal: Surg Endosc Date: 2015-06-05 Impact factor: 4.584
Authors: Aaron S Rickles; David W Dietz; George J Chang; Steven D Wexner; Mariana E Berho; Feza H Remzi; Frederick L Greene; James W Fleshman; Maher A Abbas; Walter Peters; Katia Noyes; John R T Monson; Fergal J Fleming Journal: Ann Surg Date: 2015-12 Impact factor: 12.969
Authors: A Gornicki; P Richter; W Polkowski; M Szczepkowski; L Pietrzak; L Kepka; A Rutkowski; K Bujko Journal: Eur J Surg Oncol Date: 2013-12-04 Impact factor: 4.424
Authors: S Pucciarelli; F Giandomenico; A De Paoli; T Gavaruzzi; L Lotto; G Mantello; C Barba; P Zotti; S Flora; P Del Bianco Journal: Br J Surg Date: 2016-10-05 Impact factor: 6.939
Authors: G Lezoche; M Baldarelli; Mario Guerrieri; A M Paganini; A De Sanctis; S Bartolacci; E Lezoche Journal: Surg Endosc Date: 2007-10-18 Impact factor: 4.584
Authors: Julio Garcia-Aguilar; Lindsay A Renfro; Oliver S Chow; Qian Shi; Xiomara W Carrero; Patricio B Lynn; Charles R Thomas; Emily Chan; Peter A Cataldo; Jorge E Marcet; David S Medich; Craig S Johnson; Samuel C Oommen; Bruce G Wolff; Alessio Pigazzi; Shane M McNevin; Roger K Pons; Ronald Bleday Journal: Lancet Oncol Date: 2015-10-22 Impact factor: 41.316
Authors: Katherine A Hrebinko; Katherine M Reitz; Maryam K Mohammed; Ibrahim Nassour; Andrew R Watson; Kellie E Cunningham; David S Medich; James P Celebrezze; Jennifer M Holder-Murray Journal: J Surg Oncol Date: 2021-10-27 Impact factor: 3.454
Authors: Paola Germani; Francesca Di Candido; Daniel Léonard; Dajana Cuicchi; Ugo Elmore; Marco Ettore Allaix; Vittoria Pia Barbieri; Laura D'Allens; Seraina Faes; Marika Milani; Damiano Caputo; Carmen Martinez; Jan Grosek; Valerio Caracino; Niki Christou; Sapho X Roodbeen; Umberto Bracale; Aurelia Wildeboer; Antonella Usai; Michele Benedetti; Alessandro Balani; Giuseppe Piccinni; Marco Catarci; Paolo Millo; Nicole Bouvy; Francesco Corcione; Roel Hompes; Frédéric Ris; Massimo Basti; Ales Tomazic; Eduardo Targarona; Alessandro Coppola; Andrea Pietrabissa; Dieter Hahnloser; Michel Adamina; Massimo Viola; Mario Morino; Riccardo Rosati; Gilberto Poggioli; Alex Kartheuser; Antonino Spinelli; Nicolò de Manzini Journal: Updates Surg Date: 2021-04-05
Authors: Patricio B Lynn; Maxime Van der Valk; Yvette H M Claassen; Qian Shi; Maria Widmar; Ester Bastiaannet; Cornelis Van de Velde; Julio Garcia-Aguilar Journal: Ann Surg Date: 2021-07-02 Impact factor: 12.969